A study in Chemistry A European Journal reveals that reduced MUC1 antigen density on gold nanoparticles still elicits potent ...

Breakthrough nanovaccine uses tumor cell membranes and immune-boosting polymers to enhance personalized cancer immunotherapy, ...

In the field of cancer immunotherapy, unconventional T cells (UCTs) and Chimeric Antigen Receptor (CAR) T cells have emerged as promising areas of research ...

Ineffective antigen presentation limits the adaptive immune response; however, we are now learning that the host's innate immune system may first fail to recognize the tumor as posing a danger.

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") announces that it has amended the terms of its ...

At the heart of innovation is T-win®, a groundbreaking vaccine platform that could change how we treat cancer.

New U.S. investor The Institute for Follicular Lymphoma Innovation (IFLI), a global non-profit foundation dedicated to advancing research and treatment for follicular lymphoma, invested $9 million in ...

The market worth was recorded at $3.16 billion in 2024 and is projected to escalate to $3.68 billion in 2025, unfolding at a robust compound annual growth rate CAGR of 16.1%. The proficient growth in ...

Enterome has secured $19m in new private funding to progress its EO2463 OncoMimics immunotherapy, targeting iNHL.

Myrio's PHOX2B PC-CAR T therapy gains FDA approval for human trials, promising innovative treatment for patients with ...